Utility of dose frequency adjustment in tocilizumab administration for rheumatoid arthritis

Shuntaro Saito, Yuko Kaneko, Keisuke Izumi, Tsutomu Takeuchi

研究成果: Article査読

3 被引用数 (Scopus)

抄録

Objective. To assess the utility of dose frequency adjustment of tocilizumab (TCZ) in rheumatoid arthritis (RA). Methods. Patients who received TCZ at 3-week (n = 24) or 5-week (n = 61) interval were evaluated. Results. Disease Activity Score at 28 joints based on erythrocyte sedimentation rate in the 3-week group significantly improved after 3 administrations at 3-week intervals (from 4.2 to 2.7, p = 0.001). Forty-five of the patients in the 5-week group (74%) successfully continued 5-week interval administration without disease exacerbation. Lower C-reactive protein level at TCZ initiation and shorter duration to remission achievement were key to successful dose frequency reduction. Conclusion. Adjusting the dose frequency of intravenous TCZ is a useful strategy.

本文言語English
ページ(範囲)553-557
ページ数5
ジャーナルJournal of Rheumatology
44
5
DOI
出版ステータスPublished - 2017 5 1

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

フィンガープリント 「Utility of dose frequency adjustment in tocilizumab administration for rheumatoid arthritis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル